Drugs / sabirnetug
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06511570 | Jun → Sep 2024 | Alzheimer disease | Acumen Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT04931459 | Jun 2021 → Jun 2023 | Alzheimer disease | Acumen Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06335173 | Feb 2024 → Oct 2026 expected | Alzheimer disease | Acumen Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sabirnetug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06335173 ↗ |
| Known as | ACU193 | “Sabirnetug (ACU193) is a humanized monoclonal antibody, raised against globular species of soluble AβO, that has over 650-fold greater binding affinity for AβOs over monomers...” PMID 39800458 ↗ Jan 2025 |
| Modality | Monoclonal antibody | “Sabirnetug (ACU193) is a humanized monoclonal antibody” PMID 39800458 ↗ Jan 2025 |
| Route | Intravenous | “by intravenous (IV) infusion” NCT04931459 ↗ |